WILEX AG engages in the development of diagnostic and therapeutic products for the detection and targeted treatment of various types of cancer. It operates through the following segments: Customer Specific Research (Cx), Diagnostics (Dx) and Therapeutics (Rx). The Customer Specific Research segment includes preclinical and Antibody Drug Conjugate technology services. The Diagnostics segment handles the imaging diagnostic candidate REDECTANE. The Therapeutics segment comprises of the following programmes: MESUPRON, WX-554, WX-037 as well as all preclinical and research activities of WILEX AG. The company was founded by Olaf G. Wilhelm, Manfred Schmitt, Viktor Magdolen, Heinrich Graeff, Bernd GÃ¤nsbacher, Horst Kessler, Peter Nawroth and Thomas Luther in September 1997 and is headquartered in Munich, Germany.